Browse News
Filter News
Found 169 articles
-
ProQR Announces Annual General Meeting of Shareholders and Provides Leadership Updates
6/1/2022
ProQR Therapeutics N.V. announced that its 2022 Annual General Meeting of Shareholders will take place on Thursday, June 30, 2022 at 14:00 CET via videoconference.
-
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
-
Nanoscope Therapeutics Appoints Two Pharmaceutical Industry Veterans as Scientific and Clinical Advisors
5/25/2022
Nanoscope Therapeutics , Inc., a clinical-stage biotechnology company developing gene therapies to treat retinal degenerative diseases, today announced that Naveed Shams MD, PhD, and Thomas Ciulla MD, both of whom have extensive executive leadership experience at pioneering ophthalmology companies, will serve as advisors to the Company.
-
ProQR to Present its Axiomer® RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022
5/9/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced a presentation at the Oligonucleotide and Peptide Therapeutics conference, or TIDES USA, that is being held May 9-12, 2022 in Boston, MA, U.S.
-
Sensorion Full-Year 2021 Financial Results and Business Highlights
4/28/2022
Sensorion announces its full-year 2021 financial results and provides an update on its business activities and outlook for 2022.
-
ProQR to Present at the Retinal Cell and Gene Therapy Innovation Summit and the Association for Research in Vision and Ophthalmology (ARVO) 2022
4/26/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today announced several presentations at the 7th Annual Retinal Cell and Gene Therapy Innovation Summit being held Friday, April 29, 2022 and the Annual Meeting.
-
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
4/21/2022
Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces the completion of a seed funding round.
-
ProQR to Participate in the Kempen Life Sciences Conference
4/19/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies, announced that Company management will participate in the Kempen Life Sciences Conference on April 20, 2022.
-
ProQR Therapeutics, which is developing RNA therapies for genetic eye diseases, announced Wednesday that it will be restructuring and laying off 30% of its staff.
-
ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy
4/13/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies, today provided an update on its sepofarsen program, following a comprehensive post-hoc analysis of the data from the Phase 2/3 Illuminate trial in people with CEP290-mediated Leber congenital amaurosis 10, or LCA10, a severe inherited retinal disease.
-
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
4/4/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced a presentation at the 3rd RNA Editing Summit held April 5-7 in Boston, MA, US.
-
Kenneth Frazier, executive chairman and former chief executive officer of Merck, joins former colleagues Roger Perlmutter and Roy Baynes at the well-financed company.
-
ProQR to Participate in the Cantor Virtual Rare Orphan Disease Summit - Mar 23, 2022
3/23/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will participate in the Cantor Virtual Rare Orphan Disease Summit on March 29 as part of the RNA Therapeutics in Rare Diseases panel from 2:45-3:45pm EDT.
-
Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR's Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials
3/8/2022
The Foundation Fighting Blindness is partnering with ProQR Therapeutics and InformedDNA® to accelerate patient identification and enrollment in clinical research for people with Usher syndrome or non-syndromic retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A gene.
-
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
3/7/2022
ProQR Therapeutics N.V. today announced that John Maraganore, PhD, biopharma industry leader and the former founding CEO of Alnylam Pharmaceuticals, has joined ProQR as a strategic advisor.
-
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
2/24/2022
ProQR Therapeutics N.V. reported its financial and operating results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
ProQR Therapeutics has reported that their drug sepofarsen failed to meet its primary and secondary endpoints in recent Phase II/III clinical trials.
-
ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10
2/11/2022
ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced its pivotal Phase 2/3 Illuminate trial of sepofarsen for the treatment of CEP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet its primary endpoint of Best Corrected Visual Acuity (BCVA) at Month 12.
-
ProQR to Present at Upcoming SVB Leerink Conference
2/7/2022
ProQR Therapeutics N.V., a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, announced that Company management will present at the upcoming virtual SVB Leerink 11th Annual Global Healthcare Conference.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.